Prognostic Factors in Non-Muscle-Invasive Bladder Tumors. I. Clinical Prognostic Factors: A Review of the Experience of the EORTC Genito-Urinary Group II. Biologic Prognostic Markers{A figure is presented}

European Urology, Supplements

Volumn 6, Issue 14, 2007, Pages 789-799

  Kurth, Karl Heinz ^a   Sylvester, Richard J ^b  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b European Organisation of Research and Treatment of Cancer   (Belgium)

Author keywords

Non muscle invasive bladder cancer; Prognostic factors; Scoring system for identifying risk of recurrence and progression

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DOXORUBICIN; TENIPOSIDE; THIOTEPA;

BLADDER CANCER; CANCER GRADING; CANCER GROWTH; CANCER RECURRENCE; CARCINOMA IN SITU; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DECISION MAKING; HUMAN; MEDICAL SOCIETY; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; REVIEW; RISK FACTOR; SCORING SYSTEM; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; TUMOR VOLUME; URINARY TRACT CARCINOMA; UROTHELIAL CELL CARCINOMA; UROTHELIUM;

EID: 34250816780     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.05.003     Document Type: Review

References (68)

1. Schulman C.C., Robinson M., Denis L., et al. Prophylactic chemotherapy of superficial transitional cell bladder carcinoma: an EORTC randomized trial comparing thiotepa, an epipodophyllotoxin (VM26) and TUR alone. Eur Urol 8 (1982) 207-212
2. Kurth K.H., Schroder F.H., Tunn U., et al. Adjuvant chemotherapy of superficial transitional cell bladder carcinoma: preliminary results of a European Organisation for Research on Treatment of Cancer. Randomized trial comparing doxorubicin hydrochloride, ethoglucid and transurethral resection alone. J Urol 132 (1984) 258-262
3. Bouffioux C., Denis L., Oosterlinck W., et al. Adjuvant chemotherapy of recurrent superficial transitional cell carcinoma: results of a European Organisation for Research on Treatment of Cancer randomized trial comparing intravesical instillation of thiotepa, doxorubicin and cisplatin. The European Organisation for Research on Treatment of Cancer Genitourinary Group. J Urol 148 (1992) 297-301
4. Oosterlinck W., Kurth K.H., Schroder F., Bultinck J., Hammond B., and Sylvester R. A prospective European Organisation for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary carcinoma of the bladder. J Urol 149 (1993) 749-752
5. Bouffioux C., Kurth K.H., Bono A., et al. Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of 2 European Organisation for Research and Treatment of Cancer randomized trials with mitomycin C and doxorubicin comparing early versus delayed instillations and short-term versus long-term treatment. European Organisation for Research and Treatment of Cancer Genitourinary Group. J Urol 153 (1995) 934-941
6. Newling D.W., Robinson M.R., Smith P.H., et al. Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. Eur Urol 27 (1995) 110-116
7. Kurth K., Tunn U., Ay R., et al. Adjuvant chemotherapy for superficial transitional cell bladder carcinoma: long-term results of a European Organisation for Research and Treatment of Cancer randomized trial comparing doxorubicin, ethoglucid and transurethral resection alone. J Urol 158 (1997) 378-384
8. Witjes J.A., van der Meijden A.P., Collette L., et al. Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guerin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group. Urology 52 (1998) 403-410
9. Jakse G., Hall R., Bono A., et al. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861. Eur Urol 40 (2001) 144-150
10. Van der Meijden A.P., Brausi M., Zambon V., Kirkels W., de Balincourt C., Sylvester R., and Members of the EORTC Genito-Urinary Group. Intravesical instillation of epirubicin, bacillus Calmette-Guerin and bacillus Calmette-Guerin plus isoniazid for intermediate and high risk Ta, T1 papillary carcinoma of the bladder: a European Organisation for Research and Treatment of Cancer Genito-Urinary Group randomized phase III trial. J Urol 166 (2001) 476-481
11. Mack D., Holtl W., Bassi P., et al., European Organisation for Research and Treatment of Cancer Genitourinary Group. The ablative effect of quarter dose bacillus Calmette-Guerin on a papillary marker lesion of the bladder. J Urol 165 (2001) 401-403
12. Van der Meijden A.P., Hall R.R., Macaluso M.P., Pawinsky A., Sylvester R., and Van Glabbeke M. Marker tumour responses to the sequential combination of intravesical therapy with mitomycin-C and BCG-RIVM in multiple superficial bladder tumours. Report from the European Organisation for Research and Treatment on Cancer-Genitourinary Group (EORTC 30897). Eur Urol 29 (1996) 199-203
13. De Reijke T.M., Kurth K.H., Sylvester R.J., et al., European Organisation for the Research and Treatment of Cancer-Genito-Urinary Group. Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organisation for the Research and Treatment of Cancer-Genito-Urinary Group phase III trial (30906). J Urol 173 (2005) 405-409
14. Dalesio O., Schulman C.C., Sylvester R., et al. Prognostic factors in superficial bladder tumors. A study of the European Organisation for Research on Treatment of Cancer: Genitourinary Tract Cancer Cooperative Group. J Urol 129 (1983) 730-733
15. Kurth K.H., Denis L., Bouffioux C., et al. Factors affecting recurrence and progression in superficial bladder tumours. Eur J Cancer 31A (1995) 1840-1846
16. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 49 (2006) 466-477 (discussion 475-7)
17. Kamat A.M., Gee J.R., Dinney C.P., et al. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175 (2006) 881-885
18. Quek M.L., Quinn D.I., Daneshmand S., and Stein J.P. Molecular prognostication in bladder cancer-a current perspective [review]. Eur J Cancer 39 (2003) 1501-1510
19. Dalbagni G., Parekh D.J., Ben-Porat L., Potenzoni M., Herr H.W., and Reuter V.E. Prospective evaluation of p53 as a prognostic marker in T1 transitional cell carcinoma of the bladder. BJU Int 99 (2007) 281-285
20. Yin W., Chen N., Zhang Y., et al. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder. Mod Pathol 19 (2006) 1487-1497
21. Lascombe I., Clairotte A., Fauconnet S., et al. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors. Clin Cancer Res 12 (2006) 2780-2787
22. Elsamman E.M., Fukumori T., Tanimoto S., et al. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis. BJU Int 98 (2006) 668-673
23. Kausch I., and Böhle A. Molecular aspects of bladder cancer: III. Prognostic markers of bladder cancer. Eur Urol 41 (2002) 15-29
24. Helpap B., Schmitz-Drager B.J., Hamilton P.W., et al. Molecular pathology of non-invasive urothelial carcinomas (part I). Virchows Arch 442 (2003) 309-316
25. Black P.C., Brown G.A., and Dinney C.P. Molecular markers of urothelial cancer and their use in the monitoring of superficial urothelial cancer. J Clin Oncol 24 (2006) 5528-5535
26. Lokeshwar V.B., and Selzer M.G. Urinary bladder tumor markers. Urol Oncol 24 (2006) 528-537
27. Orntoft T.F., Zieger K., and Dyrskjot L. Recent developments in molecular profiling of bladder cancer. Curr Opin Urol 16 (2006) 377-381
28. Sylvester R.J., van der Meijden A.P., Witjes J.A., and Kurth K. Bacillus Calmette-Guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol 174 (2005) 86-91 (discussion 91-2)
29. Kurth K.H., Bouffioux C., Sylvester R., van der Meijden A.P., Oosterlinck W., and Brausi M. Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group [review]. Eur Urol 37 Suppl 3 (2000) 1-9
30. Schultz I.J., Witjes J.A., Swinkels D.W., and de Kok J.B. Bladder cancer diagnosis and recurrence prognosis: comparison of markers with emphasis on survivin. Clin Chim Acta 368 (2006) 20-32
31. Brausi M., Collette L., Kurth K., et al., EORTC Genito-Urinary Tract Cancer Collaborative Group. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41 (2002) 523-531
32. Falor W.H., and Ward R.M. Cytogenetic analysis: a potential index for recurrence of early carcinoma of the bladder. J Urol 115 (1976) 49-52
33. Falor W.H., and Ward R.M. Fifty-three month persistence of ring chromosome in noninvasive bladder carcinoma. Acta Cytol 20 (1976) 272-275
34. Young A.K., Hammond E., and Middleton Jr. A.W. The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder. J Urol 122 (1979) 462-464
35. Chihara Y., Sugano K., Kobayashi A., et al. Loss of blood group A antigen expression in bladder cancer caused by allelic loss and/or methylation of the ABO gene. Lab Invest 85 (2005) 895-907
36. Pastorini P., Milano G., Toubol J., Raymond G., Cambon P., and Lalanne C.M. The diagnostic and prognostic value of urinary polyamine measurement in bladder cancer. Urol Res 9 (1981) 13-16
37. Gustafson H., Tribukait B., and Esposti P.L. The prognostic value of DNA analysis in primary carcinoma in situ of the urinary bladder. Scand J Urol Nephrol 16 (1982) 141-146
38. Herr H.W. Association of depressed mixed lymphocyte reactivity with the development of bladder carcinoma in patients with papillomas. Cancer 51 (1983) 344-347
39. Fradet Y., Cordon-Cardo C., Thomson T., et al. Cell surface antigens of human bladder cancer defined by mouse monoclonal antibodies. Proc Natl Acad Sci USA 81 (1984) 224-228
40. de Bolla A.R., Shave R.M., Fagg S.L., et al. The influence of retinoic acid receptor (RAR) status of bladder tumours on the course of the disease. Br J Urol 57 (1985) 676-679
41. Smith N.W., Strutton G.M., Walsh M.D., et al. Transferrin receptor expression in primary superficial human bladder tumours identifies patients who develop recurrences. Br J Urol 65 (1990) 339-344
42. Limas C. Proliferative state of the urothelium with benign and atypical changes. Correlation with transferrin and epidermal growth factor receptors and blood group antigens. J Pathol 171 (1993) 39-47
43. Lipponen P.K., Eskelinen M.J., and Nordling S. Nucleolar organiser regions (AgNORs) as predictors in transitional cell bladder cancer. Br J Cancer 64 (1991) 1139-1144
44. Tomobe M., Shimazui T., Uchida K., Hinotsu S., and Akaza H. Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. J Urol 162 (1999) 63-68
45. Pich A., Margaria E., Chiusa L., Bortolin P., and Palestro G. Relationship between AgNORs, MIB-1 and oncogene expression in male breast carcinoma and papillary superficial bladder neoplasm. Oncol Rep 10 (2003) 1329-1335
46. Mulder A.H., Van Hootegem J.C., Sylvester R., et al. Prognostic factors in bladder carcinoma: histologic parameters and expression of a cell cycle-related nuclear antigen (Ki-67). J Pathol 166 (1992) 37-43
47. Stavropoulos N.E., Ioackim-Velogianni E., Hastazeris K., Kitsiou E., Stefanaki S., and Agnantis N. Growth fractions in bladder cancer defined by Ki67: association with cancer grade, category and recurrence rate of superficial lesions. Br J Urol 72 (1993) 736-739
48. Cohen M.B., Waldman F.M., Carroll P.R., Kerschmann R., Chew K., and Mayall B.H. Comparison of five histopathologic methods to assess cellular proliferation in transitional cell carcinoma of the urinary bladder. Hum Pathol 24 (1993) 772-778
49. Schapers R.F., Ploem-Zaaijer J.J., Pauwels R.P., et al. Image cytometric DNA analysis in transitional cell carcinoma of the bladder. Cancer 72 (1993) 182-189
50. Cai T., Margallo E., Nesi G., Giubilei G., Rizzo M., and Bartoletti R. Prognostic value of static cytometry in transitional cell carcinoma of the bladder: recurrence rate and survival in a group of patients at 10 years follow-up. Oncol Rep 15 (2006) 213-219
51. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. J Urol 152 (1994) 388-392
52. Saint F., Le Frere Belda M.-A., Quintela R., et al. Pretreatment p53 nuclear overexpression as a prognostic marker in superficial bladder cancer treated with bacillus Calmette-Guérin (BCG). Eur Urol 45 (2004) 475-482
53. Moonen P.M., van Balken-Ory B., Kiemeney L.A., Schalken J.A., and Witjes J.A. Prognostic value of p53 for high risk superficial bladder cancer with long-term followup. J Urol 177 (2007) 80-83
54. Bochner B.H., Cote R.J., Weidner N., et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst 87 (1995) 1603-1612
55. Jeon S.H., Lee S.J., and Chang S.G. Clinical significance of urinary vascular endothelial growth factor in patients with superficial bladder tumors. Oncol Rep 8 (2001) 1265-1267
56. Stavropoulos N.E., Bouropoulos C., Ioachim I.E., et al. Prognostic significance of angiogenesis in superficial bladder cancer. Int Urol Nephrol 36 (2004) 163-167
57. van Rhijn B.W., Lurkin I., Radvanyi F., Kirkels W.J., van der Kwast T.H., and Zwarthoff E.C. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res 61 (2001) 1265-1268
58. Chan M.W., Chan L.W., Tang N.L., et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 8 (2002) 464-470
59. Tada Y., Wada M., Taguchi K., et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 62 (2002) 4048-4053
60. Christoph F., Weikert S., Kempkensteffen C., et al. Regularly methylated novel pro-apoptotic genes associated with recurrence in transitional cell carcinoma of the bladder. Int J Cancer 119 (2006) 1396-1402
61. Schultz I.J., Kiemeney L.A., Witjes J.A., et al. Survivin mRNA expression is elevated in malignant urothelial cell carcinomas and predicts time to recurrence. Anticancer Res 23 (2003) 3327-3331
62. Popov Z., Gil-Diez-De-Medina S., Ravery V., et al. Prognostic value of EGF receptor and tumor cell proliferation in bladder cancer: therapeutic implications. Urol Oncol 22 (2004) 93-101
63. Falkman K., Tribukait B., Nyman C.R., Larsson P., and Norming U. S-phase fraction in superficial urothelial carcinoma of the bladder-a prospective, long-term, follow-up study. Scand J Urol Nephrol 38 (2004) 278-284
64. Yurakh A.O., Ramos D., Calabuig-Fariñas S., et al. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol 50 (2006) 506-515 (discussion 515)
65. Shariat S.F., Ashfaq R., Sagalowsky A.I., and Lotan Y. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177 (2007) 481-487 (discussion 487)
66. Clairotte A., Lascombe I., Fauconnet S., et al. Expression of E-cadherin and alpha-, beta-, gamma-catenins in patients with bladder cancer: identification of gamma-catenin as a new prognostic marker of neoplastic progression in T1 superficial urothelial tumors. Am J Clin Pathol 125 (2006) 119-126
67. Koksal I.T., Ates M., Danisman A., et al. Reduced E-cadherin and alpha-catenin expressions have no prognostic role in bladder carcinoma. Pathol Oncol Res 12 (2006) 13-19
68. Nonomura N., Nakai Y., Nakayama M., et al. The expression of thymidine phosphorylase is a prognostic predictor for the intravesical recurrence of superficial bladder cancer. Int J Clin Oncol 11 (2006) 297-302